| Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration JS Heier, DM Brown, V Chong, JF Korobelnik, PK Kaiser, QD Nguyen, ... Ophthalmology 119 (12), 2537-2548, 2012 | 2581 | 2012 |
| Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial AJ Coles, CL Twyman, DL Arnold, JA Cohen, C Confavreux, EJ Fox, ... The lancet 380 (9856), 1829-1839, 2012 | 1245 | 2012 |
| Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes L Kappos, CH Polman, MS Freedman, G Edan, HP Hartung, DH Miller, ... Neurology 67 (7), 1242-1249, 2006 | 1016 | 2006 |
| Intravitreal Aflibercept Injection for Neovascular Age-related Macular Degeneration: Ninety-Six–Week Results of the VIEW Studies U Schmidt-Erfurth, PK Kaiser, JF Korobelnik, DM Brown, V Chong, ... Ophthalmology 121 (1), 193-201, 2014 | 933 | 2014 |
| Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the … L Kappos, MS Freedman, CH Polman, G Edan, HP Hartung, DH Miller, ... The Lancet 370 (9585), 389-397, 2007 | 731 | 2007 |
| Vitamin D as an early predictor of multiple sclerosis activity and progression A Ascherio, KL Munger, R White, K Köchert, KC Simon, CH Polman, ... JAMA neurology 71 (3), 306-314, 2014 | 671 | 2014 |
| Analysis of heterogeneous βA4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay N Ida, T Hartmann, J Pantel, J Schröder, R Zerfass, H Förstl, R Sandbrink, ... Journal of Biological Chemistry 271 (37), 22908-22914, 1996 | 617 | 1996 |
| 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study P O'Connor, M Filippi, B Arnason, G Comi, S Cook, D Goodin, HP Hartung, ... The Lancet Neurology 8 (10), 889-897, 2009 | 515 | 2009 |
| One-year outcomes of the DA VINCI Study of VEGF Trap-Eye in eyes with diabetic macular edema DV Do, QD Nguyen, D Boyer, U Schmidt-Erfurth, DM Brown, R Vitti, ... Ophthalmology 119 (8), 1658-1665, 2012 | 494 | 2012 |
| Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 … L Kappos, MS Freedman, CH Polman, G Edan, HP Hartung, DH Miller, ... The Lancet Neurology 8 (11), 987-997, 2009 | 458 | 2009 |
| Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study DM Brown, JS Heier, WL Clark, DS Boyer, R Vitti, AJ Berliner, O Zeitz, ... American journal of ophthalmology 155 (3), 429-437. e7, 2013 | 443 | 2013 |
| The DA VINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema DV Do, U Schmidt-Erfurth, VH Gonzalez, CM Gordon, M Tolentino, ... Ophthalmology 118 (9), 1819-1826, 2011 | 368 | 2011 |
| Genome‐wide meta‐analysis identifies novel multiple sclerosis susceptibility loci NA Patsopoulos, ... Annals of neurology 70 (6), 897-912, 2011 | 360 | 2011 |
| Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study JS Heier, WL Clark, DS Boyer, DM Brown, R Vitti, AJ Berliner, H Kazmi, ... Ophthalmology 121 (7), 1414-1420. e1, 2014 | 331 | 2014 |
| Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one-year results of the phase 3 GALILEO study JF Korobelnik, FG Holz, J Roider, Y Ogura, C Simader, U Schmidt-Erfurth, ... Ophthalmology 121 (1), 202-208, 2014 | 331 | 2014 |
| Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study D Boyer, J Heier, DM Brown, WL Clark, R Vitti, AJ Berliner, G Groetzbach, ... Ophthalmology 119 (5), 1024-1032, 2012 | 330 | 2012 |
| Lack of association between antimyelin antibodies and progression to multiple sclerosis J Kuhle, C Pohl, M Mehling, G Edan, MS Freedman, HP Hartung, ... New England Journal of Medicine 356 (4), 371-378, 2007 | 301 | 2007 |
| Integration of genetic risk factors into a clinical algorithm for multiple sclerosis susceptibility: a weighted genetic risk score PL De Jager, LB Chibnik, J Cui, J Reischl, S Lehr, KC Simon, C Aubin, ... The Lancet Neurology 8 (12), 1111-1119, 2009 | 294 | 2009 |
| VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study FG Holz, J Roider, Y Ogura, JF Korobelnik, C Simader, G Groetzbach, ... British Journal of Ophthalmology 97 (3), 278-284, 2013 | 286 | 2013 |
| Beta A4-amyloid protein precursor mRNA isoforms without exon 15 are ubiquitously expressed in rat tissues including brain, but not in neurons. R Sandbrink, CL Masters, K Beyreuther Journal of Biological Chemistry 269 (2), 1510-1517, 1994 | 227 | 1994 |
Ludwig KapposUniversity Hospital BaselAdresse e-mail validée de uhbs.ch
